ALGN vs. RDY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALGN and RDY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ALGN’s market capitalization stands at 14.27 billion USD, while RDY’s is 12.55 billion USD, indicating their market valuations are broadly comparable.
ALGN’s beta of 1.64 points to significantly higher volatility compared to RDY (beta: 0.39), suggesting ALGN has greater potential for both gains and losses relative to market movements.
RDY is an American Depositary Receipt (ADR), allowing U.S. investors direct exposure to its non-U.S. operations. ALGN, on the other hand, is a domestic entity.
| Symbol | ALGN | RDY |
|---|---|---|
| Company Name | Align Technology, Inc. | Dr. Reddy's Laboratories Limited |
| Country | US | IN |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Drug Manufacturers - Specialty & Generic |
| CEO | Joseph M. Hogan | Erez Israeli |
| Price | 196.82 USD | 15.08 USD |
| Market Cap | 14.27 billion USD | 12.55 billion USD |
| Beta | 1.64 | 0.39 |
| Exchange | NASDAQ | NYSE |
| IPO Date | January 30, 2001 | April 11, 2001 |
| ADR | No | Yes |
Historical Performance
This chart compares the performance of ALGN and RDY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALGN
10.67%
Medical - Devices Industry
- Max
- 49.04%
- Q3
- 9.53%
- Median
- -7.46%
- Q1
- -32.83%
- Min
- -82.64%
In the upper quartile for the Medical - Devices industry, ALGN’s Return on Equity of 10.67% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
RDY
18.08%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 51.32%
- Q3
- 9.89%
- Median
- -3.37%
- Q1
- -20.99%
- Min
- -36.07%
In the upper quartile for the Drug Manufacturers - Specialty & Generic industry, RDY’s Return on Equity of 18.08% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
ALGN
9.78%
Medical - Devices Industry
- Max
- 21.88%
- Q3
- 6.63%
- Median
- -1.11%
- Q1
- -21.08%
- Min
- -51.95%
In the upper quartile for the Medical - Devices industry, ALGN’s Return on Invested Capital of 9.78% signifies a highly effective use of its capital to generate profits when compared to its peers.
RDY
13.27%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 22.54%
- Q3
- 8.45%
- Median
- 1.42%
- Q1
- -9.01%
- Min
- -28.41%
In the upper quartile for the Drug Manufacturers - Specialty & Generic industry, RDY’s Return on Invested Capital of 13.27% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
ALGN
10.29%
Medical - Devices Industry
- Max
- 44.80%
- Q3
- 9.77%
- Median
- -5.53%
- Q1
- -29.37%
- Min
- -87.68%
A Net Profit Margin of 10.29% places ALGN in the upper quartile for the Medical - Devices industry, signifying strong profitability and more effective cost management than most of its peers.
RDY
17.37%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 40.33%
- Q3
- 11.92%
- Median
- -0.45%
- Q1
- -13.07%
- Min
- -34.27%
A Net Profit Margin of 17.37% places RDY in the upper quartile for the Drug Manufacturers - Specialty & Generic industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
ALGN
14.69%
Medical - Devices Industry
- Max
- 30.13%
- Q3
- 13.12%
- Median
- 3.47%
- Q1
- -24.42%
- Min
- -80.56%
An Operating Profit Margin of 14.69% places ALGN in the upper quartile for the Medical - Devices industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
RDY
21.95%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 46.91%
- Q3
- 19.02%
- Median
- 6.23%
- Q1
- -11.23%
- Min
- -51.89%
An Operating Profit Margin of 21.95% places RDY in the upper quartile for the Drug Manufacturers - Specialty & Generic industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ALGN | RDY |
|---|---|---|
| Return on Equity (TTM) | 10.67% | 18.08% |
| Return on Assets (TTM) | 6.71% | 11.47% |
| Return on Invested Capital (TTM) | 9.78% | 13.27% |
| Net Profit Margin (TTM) | 10.29% | 17.37% |
| Operating Profit Margin (TTM) | 14.69% | 21.95% |
| Gross Profit Margin (TTM) | 69.87% | 57.17% |
Financial Strength
Current Ratio
ALGN
1.21
Medical - Devices Industry
- Max
- 12.68
- Q3
- 6.30
- Median
- 4.05
- Q1
- 1.85
- Min
- 0.01
ALGN’s Current Ratio of 1.21 falls into the lower quartile for the Medical - Devices industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
RDY
1.92
Drug Manufacturers - Specialty & Generic Industry
- Max
- 5.74
- Q3
- 3.37
- Median
- 2.64
- Q1
- 1.73
- Min
- 0.88
RDY’s Current Ratio of 1.92 aligns with the median group of the Drug Manufacturers - Specialty & Generic industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ALGN
0.03
Medical - Devices Industry
- Max
- 2.34
- Q3
- 1.09
- Median
- 0.37
- Q1
- 0.08
- Min
- 0.00
Falling into the lower quartile for the Medical - Devices industry, ALGN’s Debt-to-Equity Ratio of 0.03 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
RDY
0.14
Drug Manufacturers - Specialty & Generic Industry
- Max
- 1.45
- Q3
- 1.06
- Median
- 0.62
- Q1
- 0.13
- Min
- 0.00
RDY’s Debt-to-Equity Ratio of 0.14 is typical for the Drug Manufacturers - Specialty & Generic industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
ALGN
--
Medical - Devices Industry
- Max
- 18.18
- Q3
- 7.53
- Median
- 0.85
- Q1
- -9.80
- Min
- -33.94
Interest Coverage Ratio data for ALGN is currently unavailable.
RDY
32.89
Drug Manufacturers - Specialty & Generic Industry
- Max
- 10.17
- Q3
- 3.39
- Median
- 0.85
- Q1
- -2.63
- Min
- -5.84
With an Interest Coverage Ratio of 32.89, RDY demonstrates a superior capacity to service its debt, placing it well above the typical range for the Drug Manufacturers - Specialty & Generic industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | ALGN | RDY |
|---|---|---|
| Current Ratio (TTM) | 1.21 | 1.92 |
| Quick Ratio (TTM) | 1.08 | 1.37 |
| Debt-to-Equity Ratio (TTM) | 0.03 | 0.14 |
| Debt-to-Asset Ratio (TTM) | 0.02 | 0.09 |
| Net Debt-to-EBITDA Ratio (TTM) | -0.94 | 0.35 |
| Interest Coverage Ratio (TTM) | -- | 32.89 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALGN and RDY. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ALGN
0.00%
Medical - Devices Industry
- Max
- 3.57%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
RDY
0.61%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 9.29%
- Q3
- 0.31%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.61%, RDY offers a more attractive income stream than most of its peers in the Drug Manufacturers - Specialty & Generic industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
ALGN
0.00%
Medical - Devices Industry
- Max
- 102.12%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
RDY
11.78%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 125.42%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RDY’s Dividend Payout Ratio of 11.78% is in the upper quartile for the Drug Manufacturers - Specialty & Generic industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | ALGN | RDY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.61% |
| Dividend Payout Ratio (TTM) | 0.00% | 11.78% |
Valuation
Price-to-Earnings Ratio
ALGN
35.35
Medical - Devices Industry
- Max
- 90.56
- Q3
- 56.92
- Median
- 43.19
- Q1
- 21.79
- Min
- 5.55
ALGN’s P/E Ratio of 35.35 is within the middle range for the Medical - Devices industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
RDY
19.29
Drug Manufacturers - Specialty & Generic Industry
- Max
- 40.89
- Q3
- 28.12
- Median
- 23.94
- Q1
- 18.79
- Min
- 7.76
RDY’s P/E Ratio of 19.29 is within the middle range for the Drug Manufacturers - Specialty & Generic industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ALGN
3.34
Medical - Devices Industry
- Max
- 6.56
- Q3
- 3.52
- Median
- 2.22
- Q1
- 0.55
- Min
- 0.03
ALGN’s Forward PEG Ratio of 3.34 is within the middle range of its peers in the Medical - Devices industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
RDY
-5.44
Drug Manufacturers - Specialty & Generic Industry
- Max
- 4.19
- Q3
- 2.94
- Median
- 1.47
- Q1
- 0.35
- Min
- 0.00
RDY has a negative Forward PEG Ratio of -5.44. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
Price-to-Sales Ratio
ALGN
3.58
Medical - Devices Industry
- Max
- 15.74
- Q3
- 8.12
- Median
- 3.40
- Q1
- 2.37
- Min
- 0.42
ALGN’s P/S Ratio of 3.58 aligns with the market consensus for the Medical - Devices industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RDY
3.35
Drug Manufacturers - Specialty & Generic Industry
- Max
- 7.49
- Q3
- 4.45
- Median
- 2.12
- Q1
- 1.21
- Min
- 0.25
RDY’s P/S Ratio of 3.35 aligns with the market consensus for the Drug Manufacturers - Specialty & Generic industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
ALGN
3.82
Medical - Devices Industry
- Max
- 16.65
- Q3
- 8.03
- Median
- 3.73
- Q1
- 1.92
- Min
- 0.65
ALGN’s P/B Ratio of 3.82 is within the conventional range for the Medical - Devices industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
RDY
3.27
Drug Manufacturers - Specialty & Generic Industry
- Max
- 4.93
- Q3
- 3.95
- Median
- 2.14
- Q1
- 1.30
- Min
- 0.13
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - Specialty & Generic industry.
Valuation at a Glance
| Symbol | ALGN | RDY |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 35.35 | 19.29 |
| Forward PEG Ratio (TTM) | 3.34 | -5.44 |
| Price-to-Sales Ratio (P/S, TTM) | 3.58 | 3.35 |
| Price-to-Book Ratio (P/B, TTM) | 3.82 | 3.27 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 22.62 | 71.17 |
| EV-to-EBITDA (TTM) | 16.80 | 12.30 |
| EV-to-Sales (TTM) | 3.39 | 3.45 |